MediWound (NASDAQ:MDWD – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Risk and Volatility
MediWound has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Valuation and Earnings
This table compares MediWound and Silence Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 10.57 | -$23.88 million | ($2.26) | -6.17 |
| Silence Therapeutics | $560,000.00 | 590.50 | -$88.61 million | ($1.59) | -4.40 |
MediWound has higher revenue and earnings than Silence Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings for MediWound and Silence Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 1 | 2 | 0 | 2.25 |
| Silence Therapeutics | 1 | 0 | 3 | 1 | 2.80 |
MediWound currently has a consensus price target of $34.00, indicating a potential upside of 143.73%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 685.71%. Given Silence Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than MediWound.
Insider & Institutional Ownership
46.8% of MediWound shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 9.2% of MediWound shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares MediWound and Silence Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -180.30% | -67.22% | -31.87% |
| Silence Therapeutics | -8,943.86% | -105.34% | -52.79% |
Summary
Silence Therapeutics beats MediWound on 9 of the 15 factors compared between the two stocks.
About MediWound
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
